Focus: Lonza is a leading Contract Development and Manufacturing Organization (CDMO) headquartered in Basel, Switzerland, serving the pharmaceutical and biotech industries. With 10,001–50,000 employees and publicly traded status (ticker: LONN), it operates at significant scale as a critical outsourcing partner.
Profile data last refreshed 15h ago · AI intelligence enriched 1mo ago
Hot — 514 jobs added in 30d
Net +218 (514 new, 296 removed). Aggressive expansion phase.
Lonza is an excellent fit for manufacturing, engineering, and operations professionals seeking stability and scale; less ideal for those pursuing drug discovery or clinical development careers.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Lonza
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Lonza's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Lonza Group stock pre-market at EUR 658.60: contract manufacturing group - ad-hoc-news.de
Lonza Group stock pre-market at EUR 658.60: contract manufacturing group ad-hoc-news.de
CPHI Milan 2026 review - Nutrition Insight
CPHI Milan 2026 review Nutrition Insight
Qurient teams with Lonza to advance dual‑payload ADC platform using CDK7 drug - CHOSUNBIZ - Chosunbiz
Qurient teams with Lonza to advance dual‑payload ADC platform using CDK7 drug - CHOSUNBIZ Chosunbiz
Lonza upgrades organic growth model - The Pharma Letter
Lonza upgrades organic growth model The Pharma Letter
Lonza aims to grow and become even more profitable - blue News
Lonza aims to grow and become even more profitable blue News
Lonza sets new mid-term targets, confirms 2026 outlook - Reuters
Lonza sets new mid-term targets, confirms 2026 outlook Reuters
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo